The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Open accessAbstract
BACKGROUND: Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many myeloproliferative neoplasms, but the molecular pathogenesis of myeloproliferative neoplasms with nonmutated JAK2 is obscure, and the diagnosis of these neoplasms remains a challenge. METHODS: We performed exome sequencing of samples obtained from 151 patients with myeloproliferative neoplasms. The mutation status of the gene encoding calreticulin (CALR) was assessed in an additional 1345 hematologic cancers, 1517 other cancers, and 550 controls. We established phylogenetic trees using hematopoietic colonies. We assessed calreticulin subcellular localization using immunofluorescence and flow cytometry. RESULTS: Exome sequencing identified 1498 mutations in 151 patients, with medians of 6.5, 6.5, and 13.0 mutations per patient in samples of polycythemia vera, essential thrombocythemia, and myelofibrosis, respectively. Somatic CALR mutations were found in 70 to 84% of samples of myeloproliferative neoplasms with nonmutated JAK2, in 8% of myelodysplasia samples, in occasional samples of other myeloid cancers, and in none of the other cancers. A total of 148 CALR mutations were identified with 19 distinct variants. Mutations were located in exon 9 and generated a +1 base-pair frameshift, which would result in a mutant protein with a novel C-terminal. Mutant calreticulin was observed in the endoplasmic reticulum without increased cell-surface or Golgi accumulation. Patients with myeloproliferative neoplasms carrying CALR mutations presented with higher platelet counts and lower hemoglobin levels than patients with mutated JAK2. Mutation of CALR was detected in hematopoietic stem and progenitor cells. Clonal analyses showed CALR mutations in the earliest phylogenetic node, a finding consistent with its role as an initiating mutation in some patients. CONCLUSIONS: Somatic mutations in the endoplasmic reticulum chaperone CALR were found in a majority of patients with myeloproliferative neoplasms with nonmutated JAK2. (Funded by the Kay Kendall Leukaemia Fund and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“But many of the most commonly seen mutations in CHIP are also recurrent drivers of AML 64, myelodysplastic syndrome (MDS) 65–67, myeloproliferative neoplasms 68, and certain lymphomas 69,70.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [68]
In the citing paper
“Calreticulin gene (CALR) mutations frequently occur in Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), primary myelofibrosis (PMF), and polycythemia vera (PV) [188–190].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Self-citationA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,062
Self-citationLevine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationClinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Chao MP, 2010, Sci Transl Med, 2, 63ra94
Cited by
Sorted by citations
Items 301–400 of 1,002
Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations
Gangat, N., & Tefferi, A. (2020) · American Journal of Hematology · doi:10.1002/ajh.26067 · Cited by 52
Calreticulin mutations in Chinese with primary myelofibrosis
Li, B., Xu, J., Wang, J., Gale, R. P., Xu, Z., Cui, Y., Yang, L., Xing, R., Ai, X., Qin, T., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.109249 · Cited by 51
Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter
Barosi, G. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.07.004 · Cited by 51
Lussana, F., Carobbio, A., Randi, M. L., Elena, C., Rumi, E., Finazzi, G., Bertozzi, I., Pieri, L., Ruggeri, M., Palandri, F., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13080 · Cited by 51
Self-citationMyeloproliferative neoplasms in children
Hofmann, I. (2015) · Journal of Hematopathology · doi:10.1007/s12308-015-0256-1 · Cited by 51
Myeloproliferative neoplasms: Current molecular biology and genetics
Saeidi, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.004 · Cited by 53
Multiple Roles of Glycans in Hematological Malignancies
Pang, X., Li, H., Guan, F., & Li, X. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00364 · Cited by 55
Chen, E., Ahn, J. S., Massie, C. E., Clynes, D., Godfrey, A. L., Li, J., Park, H. J., Nangalia, J., Silber, Y., Mullally, A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401873111 · Cited by 53
Self-citationWu, Z., Zhang, X., Xu, X. L., Chen, Y., Hu, T., Kang, Z., Li, S., Wang, H., Liu, W., Ma, X., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0048-6 · Cited by 50
Kjær, L., Cordua, S., Holmström, M. O., Thomassen, M., Kruse, T. A., Pallisgaard, N., Larsen, T. S., de Stricker, K., Skov, V., & Hasselbalch, H. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165336 · Cited by 50
Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia
Higgins, A. S., & Shah, M. V. (2020) · Genes · doi:10.3390/genes11070749 · Cited by 51
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
Pecquet, C., Papadopoulos, N., Balligand, T., Chachoua, I., Tisserand, A., Vertenoeil, G., Nédélec, A., Vertommen, D., Roy, A., Marty, C., et al. (2022) · Blood · doi:10.1182/blood.2022016846 · Cited by 49
Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia
Ling, V., Straube, J., Godfrey, W. A., Haldar, R., Janardhanan, Y., Cooper, L. T., Bruedigam, C., Cooper, E., Shirazi, P. T., Jacquelin, S., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01755-2 · Cited by 49
Ruxolitinib is an effective treatment for CALR ‐positive patients with myelofibrosis
Guglielmelli, P., Rotunno, G., Bogani, C., Mannarelli, C., Giunti, L., Provenzano, A., Giglio, S., Squires, M. S., Stalbovskaya, V., Gopalakrishna, P., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13644 · Cited by 49
Self-citationBarosi, G., Tefferi, A., Besses, C., Birgegård, G., Cervantes, F., Finazzi, G., Gisslinger, H., Grießhammer, M., Harrison, C. N., Hehlmann, R., et al. (2014) · Leukemia · doi:10.1038/leu.2014.250 · Cited by 51
Self-citationMichiels, J. J., Berneman, Z. N., Schroyens, W., & Raeve, H. D. (2014) · Acta Haematologica · doi:10.1159/000358580 · Cited by 50
Jäger, R., Harutyunyan, A. S., Rumi, E., Pietra, D., Berg, T., Olcaydu, D., Houlston, R. S., Cazzola, M., & Královics, R. (2014) · American Journal of Hematology · doi:10.1002/ajh.23842 · Cited by 49
Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling
Osorio, F. G., Soria‐Valles, C., Santiago‐Fernández, O., Bernal, T., Mittelbrunn, M., Colado, E., Rodríguez, F. J., Bonzón‐Kulichenko, E., Vázquez, J., Porta-de-la-Riva, M., et al. (2015) · Nature Medicine · doi:10.1038/nm.4013 · Cited by 51
Self-citationBalligand, T., Achouri, Y., Pecquet, C., Chachoua, I., Nivarthi, H., Marty, C., Vainchenker, W., Plo, I., Královics, R., & Constantinescu, S. N. (2016) · Leukemia · doi:10.1038/leu.2016.47 · Cited by 49
Recent advances in understanding myelofibrosis and essential thrombocythemia
Vainchenker, W., Constantinescu, S. N., & Plo, I. (2016) · F1000Research · doi:10.12688/f1000research.8081.1 · Cited by 54
Ramos, F., Spanish Group for Myelodysplastic Syndromes (GESMD), Robledo, C., Izquierdo-García, F. M., Suárez‐Vilela, D., Benito, R., Fuertes, M., Insunza, A., Barragán, E., Rey, M. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9026 · Cited by 49
Zini, R., Guglielmelli, P., Pietra, D., Rumi, E., Rossi, C., Rontauroli, S., Genovese, E., Fanelli, T., Calabresi, L., Bianchi, E., et al. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0010-2 · Cited by 49
Self-citationWang, Z., Liu, F., Ye, S., Jiang, P., Yu, X., Xu, J., Du, X., Ma, L., Cao, H., Yuan, C., et al. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.12.031 · Cited by 49
Loscocco, G. G., Guglielmelli, P., & Vannucchi, A. M. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s287944 · Cited by 49
Self-citationFunctional Consequences of Mutations in Myeloproliferative Neoplasms
Constantinescu, S. N., Vainchenker, W., Levy, G., & Papadopoulos, N. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000578 · Cited by 51
Epigenetics in Myeloproliferative Neoplasms
McPherson, S., McMullin, M. F., & Mills, K. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13095 · Cited by 50
JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
Bader, M. S., & Meyer, S. C. (2022) · Pharmaceuticals · doi:10.3390/ph15020160 · Cited by 50
Sobas, M., Kiladjian, J., Beauverd, Y., Curto‐García, N., Sadjadian, P., Shih, L., Devos, T., Krochmalczyk, D., Galli, S., Bieniaszewska, M., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007201 · Cited by 48
Self-citationFu, R., Xuan, M., Zhou, Y., Sun, T., Bai, J., Cao, Z., Zhang, L., Li, H., Zhang, D., Zhang, X., et al. (2014) · Leukemia · doi:10.1038/leu.2014.138 · Cited by 48
Lin, Y., Liu, E., Sun, Q., Ma, J., Li, Q., Cao, Z., Wang, J., Jia, Y., Zhang, H., Song, Z., et al. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpalp51xdixddv · Cited by 48
Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms
Meyer, S. C. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.04.003 · Cited by 48
Senín, A., Fernández‐Rodríguez, C., Bellosillo, B., Camacho, L., Longarón, R., Angona, A., Besses, C., & Álvarez‐Larrán, A. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3193-5 · Cited by 48
The Role of New Technologies in Myeloproliferative Neoplasms
Palumbo, G. A., Stella, S., Pennisi, M. S., Pirosa, C., Fermo, E., Fabris, S., Cattaneo, D., & Iurlo, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00321 · Cited by 48
Dynamin 2–dependent endocytosis is required for normal megakaryocyte development in mice
Bender, M., Giannini, S., Grozovsky, R., Jönsson, T., Christensen, H., Pluthero, F. G., Ko, A., Mullally, A., Kahr, W. H. A., Hoffmeister, K. M., et al. (2014) · Blood · doi:10.1182/blood-2014-07-587857 · Cited by 47
Gangat, N., Wassie, E. A., Lasho, T. L., Finke, C. M., Ketterling, R. P., Hanson, C. A., Pardanani, A. D., Wolanskyj, A. P., Maffioli, M., Casalone, R., et al. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12389 · Cited by 46
Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy
Hahn, C. N., Venugopal, P., Scott, H. S., & Hiwase, D. (2014) · Immunological Reviews · doi:10.1111/imr.12241 · Cited by 46
Leukemic transformation in myeloproliferative neoplasms: Therapy-related or unrelated?
Björkholm, M., Hultcrantz, M. L., & Derolf, Å. R. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.07.003 · Cited by 47
Debureaux, P.-É., Cassinat, B., Soret‐Dulphy, J., Mora, B., Verger, E., Maslah, N., Plessier, A., Rautou, P., Ollivier‐Hourmand, I., de Lédinghen, V., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002414 · Cited by 47
Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults
Kucine, N. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00571-8 · Cited by 45
Stockklausner, C., Duffert, C. M., Cario, H., Knöfler, R., Streif, W., Kulozik, A. E., & (GPOH), O. B. O. T.-P. S. D. G. F. T. U. H. (. A. O. G. F. P. O. U. H. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04485-0 · Cited by 45
Refractory anemia with ring sideroblasts and RARS with thrombocytosis
Patnaik, M. M., & Tefferi, A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24038 · Cited by 45
Engle, E. K., Fisher, D. A. C., Miller, C. A., McLellan, M. D., Fulton, R. S., Moore, D. M., Wilson, R. K., Ley, T. J., & Oh, S. T. (2014) · Leukemia · doi:10.1038/leu.2014.289 · Cited by 45
A CALR Mutation Preceding BCR-ABL1 in an Atypical Myeloproliferative Neoplasm
Cabagnols, X., Cayuela, J., & Vainchenker, W. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1413718 · Cited by 45
Jamieson, C. H. M., Hasserjian, R. P., Gotlib, J. R., Cortes, J. E., Stone, R. M., Talpaz, M., Thiele, J., Rodig, S. J., & Pozdnyakova, O. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0644-4 · Cited by 45
Bartels, S., Schipper, E., Hasemeier, B., Kreipe, H. H., & Lehmann, U. (2016) · Oncotarget · doi:10.18632/oncotarget.8310 · Cited by 46
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Bryan, J. C., & Verstovšek, S. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3012-z · Cited by 45
Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms
Mori, T., Nagata, Y., Makishima, H., Sanada, M., Shiozawa, Y., Kon, A., Yoshizato, T., Sato‐Otsubo, A., Kataoka, K., Shiraishi, Y., et al. (2016) · Leukemia · doi:10.1038/leu.2016.212 · Cited by 45
Myelofibrosis: to transplant or not to transplant?
Devlin, R., & Gupta, V. K. (2016) · Hematology · doi:10.1182/asheducation-2016.1.543 · Cited by 45
Chang, Y., Lin, H., Chiang, Y., Chen, C. G., Huang, L., Wang, W., Cheng, C., Lin, J., Chang, Y., Chang, M., et al. (2017) · Medical Oncology · doi:10.1007/s12032-017-0944-z · Cited by 45
Aguilera-Diaz, A., Vázquez, I., Ariceta, B., Mañú, A., Blasco‐Iturri, Z., Palomino‐Echeverría, S., Larráyoz, M. J., García‐Sánz, R., Prieto-Conde, I., Chillón, C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227986 · Cited by 45
Benlabiod, C., Cacemiro, M. D. C., Nédélec, A., Edmond, V., Muller, D., Rameau, P., Touchard, L., Gonin, P., Constantinescu, S. N., Raslová, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18691-3 · Cited by 45
Patnaik, M. M., & Tefferi, A. (2019) · American Journal of Hematology · doi:10.1002/ajh.25397 · Cited by 46
Roles of Calreticulin in Protein Folding, Immunity, Calcium Signaling and Cell Transformation
Venkatesan, A., Satin, L. S., & Raghavan, M. (2021) · Progress in molecular and subcellular biology · doi:10.1007/978-3-030-67696-4_7 · Cited by 44
Chronic neutrophilic leukemia: new science and new diagnostic criteria
Szuber, N., & Tefferi, A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0049-8 · Cited by 44
Chi, J., Manoloukos, M., Pierides, C., Nicolaidou, V., Nicolaou, K. A., Kleopa, M., Vassiliou, G. S., & Costeas, P. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2232-8 · Cited by 43
Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis
Plompen, E. P. C., Valk, P. J. M., Chu, I., Murad, S. D., Plessier, A., Turón, F., Trebicka, J., Primignani, M., García‐Pagán, J. C., Valla, D. C., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.120857 · Cited by 43
Pathogenesis of Myeloproliferative Disorders
Nangalia, J., Grinfeld, J., & Green, A. R. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044454 · Cited by 48
Self-citationTheocharides, A. P. A., Lundberg, P., Lakkaraju, A. K., Lysenko, V., Myburgh, R., Aguzzi, A., Skoda, R. C., & Manz, M. G. (2016) · Blood · doi:10.1182/blood-2016-02-696310 · Cited by 43
Balligand, T., Achouri, Y., Pecquet, C., Gaudray, G., Colau, D., Hug, E., Rahmani, Y., Stroobant, V., Plo, I., Vainchenker, W., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0538-1 · Cited by 43
Concordance for clonal hematopoiesis is limited in elderly twins
Fabre, M. A., McKerrell, T., Zwiebel, M., Vijayabaskar, M. S., Park, N., Wells, P. M., Rad, R., Deloukas, P., Small, K. S., Steves, C. J., et al. (2019) · Blood · doi:10.1182/blood.2019001807 · Cited by 43
Novel therapeutics in myeloproliferative neoplasms
Venugopal, S., & Mascarenhas, J. O. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00995-y · Cited by 45
Mutant Calreticulin in the Myeloproliferative Neoplasms
Prins, D., Arias, C. G., Klampfl, T., Grinfeld, J., & Green, A. R. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000333 · Cited by 44
Self-citationIbarra, J., Elbanna, Y. A., Kurylowicz, K., Ciboddo, M., Greenbaum, H. S., Arellano, N., Rodriguez, D., Evers, M., Bock-Hughes, A., Liu, C., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0144 · Cited by 42
Rai, S., Zhang, Y., Grockowiak, É., Kimmerlin, Q., Hansen, N., Stoll, C. B., Usart, M., Paz, D. L., Hao-Shen, H., Zhu, Y., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011338 · Cited by 46
Incidence of CALR mutations in patients with splanchnic vein thrombosis
Haslam, K., & Langabeer, S. E. (2014) · British Journal of Haematology · doi:10.1111/bjh.13121 · Cited by 42
Role of tumour angiogenesis in haematological malignancies
Medinger, M., & Passweg, J. R. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.14050 · Cited by 42
The Role of Inflammation and Inflammasome in Myeloproliferative Disease
Longhitano, L., Volti, G. L., Giallongo, C., Spampinato, M., Barbagallo, I. A., Rosa, M. D., Romano, A., Avola, R., Tibullo, D., & Palumbo, G. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082334 · Cited by 42
Large-scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers
Feusier, J. E., Arunachalam, S., Tashi, T., Baker, M. J., Vansant-Webb, C. H., Ferdig, A., Welm, B. E., Rodríguez-Flores, J. L., Ours, C., Jorde, L. B., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0094 · Cited by 45
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia
Rumi, E., Bertozzi, I., Casetti, I. C., Roncoroni, E., Cavalloni, C., Bellini, M., Sant’Antonio, E., Gotti, M., Ferretti, V. V., Milanesi, C., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.131458 · Cited by 42
Gigoux, M., Holmström, M. O., Zappasodi, R., Park, J. J., Pourpe, S., Bozkus, C. C., Mangarin, L. M. B., Redmond, D., Verma, S., Schad, S. E., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4380 · Cited by 41
Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
Tibes, R., & Mesa, R. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-18 · Cited by 41
Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia
Usseglio, F., Beaufils, N., Calleja, A., Raynaud, S., & Gabert, J. A. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.08.006 · Cited by 41
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms
Rumi, E., & Cazzola, M. (2017) · British Journal of Haematology · doi:10.1111/bjh.14713 · Cited by 41
Recent insights regarding the molecular basis of myeloproliferative neoplasms
Jang, M., & Choi, C. W. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.317 · Cited by 42
Loscocco, G. G., Guglielmelli, P., Gangat, N., Rossi, E., Mannarelli, C., Betti, S., Maccari, C., Ramundo, F., Jadoon, Y., Gesullo, F., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26332 · Cited by 41
Self-citationMyelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape
Tefferi, A., Gangat, N., Pardanani, A. D., & Crispino, J. D. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2930 · Cited by 43
Wu, S., Li, Z., Gnatenko, D. V., Zhang, B., Zhao, L. H., Malone, L. E., Markova, N. G., Mantle, T. J., Nesbitt, N. M., & Bahou, W. F. (2016) · Blood · doi:10.1182/blood-2016-02-696997 · Cited by 41
Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance
Zhou, W., Sun, W., Yung, M. M. H., Dai, S., Cai, Y., Chen, C., Meng, Y., Lee, J. B., Braisted, J. C., Xu, Y., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0238-8 · Cited by 41
Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera
Tsuruta-Kishino, T., Koya, J., Kataoka, K., Narukawa, K., Sumitomo, Y., Kobayashi, H., Sato, T., & Kurokawa, M. (2017) · Oncogene · doi:10.1038/onc.2016.478 · Cited by 41
Reis, E. S., Buonpane, R. A., Celik, H., Marty, C., Lei, A., Jobe, F., Rupar, M. J., Zhang, Y., DiMatteo, D., Awdew, R., et al. (2024) · Blood · doi:10.1182/blood.2024024373 · Cited by 40
Chronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and management
Elliott, M. A., & Tefferi, A. (2014) · American Journal of Hematology · doi:10.1002/ajh.23667 · Cited by 40
Lysyl oxidase is associated with increased thrombosis and platelet reactivity
Matsuura, S., Mi, R., Koupenova, M., Eliades, A., Patterson, S., Toselli, P. A., Thon, J. N., Italiano, J. E., Trackman, P. C., Papadantonakis, N., et al. (2016) · Blood · doi:10.1182/blood-2015-02-629667 · Cited by 40
Kang, M.-G., Choi, H.-W., Lee, J. H., Choi, H., Choi, H.-J., Shin, J.-H., Suh, S., Szardenings, M., Kim, H. R., & Shin, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10958 · Cited by 40
Holmström, M. O., Ahmad, S. M., Klausen, U., Bendtsen, S. K., Martinenaite, E., Riley, C. H., Svane, I. M., Kjær, L., Skov, V., Ellervik, C., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-018-0166-4 · Cited by 40
Skov, V. (2020) · Cancers · doi:10.3390/cancers12082194 · Cited by 40
Smoking and philadelphia‐negative chronic myeloproliferative neoplasms
Sørensen, A. L., & Hasselbalch, H. C. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12684 · Cited by 40
Beauverd, Y., & Samii, K. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1628-5 · Cited by 40
Thrombosis in myeloproliferative neoplasms: A clinical and pathophysiological perspective
Kelliher, S., & Falanga, A. (2021) · Thrombosis Update · doi:10.1016/j.tru.2021.100081 · Cited by 39
Targeting human CALR‐mutated MPN progenitors with a neoepitope‐directed monoclonal antibody
Tvorogov, D., Thompson-Peach, C. A. L., Foßelteder, J., Dottore, M., Stomski, F. C., Onnesha, S. A., Lim, K. S., Moretti, P. A. B., Pitson, S. M., Ross, D. M., et al. (2022) · EMBO Reports · doi:10.15252/embr.202152904 · Cited by 40
CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum
Guglielmelli, P., Nangalia, J., Green, A. R., & Vannucchi, A. M. (2014) · American Journal of Hematology · doi:10.1002/ajh.23678 · Cited by 39
Self-citationHigh Resolution Melting Analysis: A Rapid and Accurate Method to Detect CALR Mutations
Bilbao, C., Santana, G. S., Moreno, M. J., Torres, L., Santana-Lopez, G., Rodríguez‐Medina, C., Perera, M., Bellosillo, B., de la Iglesia, S., Molero, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103511 · Cited by 39
Molecular biomarkers of thrombosis in myeloproliferative neoplasms
Barbui, T., & Falanga, A. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30102-5 · Cited by 39
Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era
Falchi, L., Kantarjian, H. M., & Verstovšek, S. (2017) · Leukemia · doi:10.1038/leu.2017.150 · Cited by 39
Bartalucci, N., Calabresi, L., Balliu, M., Martinelli, S., Rossi, M. C., Villeval, J., Annunziato, F., Guglielmelli, P., & Vannucchi, A. M. (2017) · Oncotarget · doi:10.18632/oncotarget.18073 · Cited by 39
Self-citationNuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Yan, D., Pomicter, A. D., Tantravahi, S. K., Mason, C. C., Senina, A. V., Ahmann, J. M., Wang, Q., Than, H., Patel, A. B., Heaton, W. L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0959 · Cited by 41
Bone marrow niche dysregulation in myeloproliferative neoplasms
Curto‐García, N., Harrison, C. N., & McLornan, D. P. (2020) · Haematologica · doi:10.3324/haematol.2019.243121 · Cited by 39
Self-citationChallenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms
Brkić, Š., & Meyer, S. C. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000516 · Cited by 40
The Role of Megakaryocytes in Myelofibrosis
Melo‐Cardenas, J., Migliaccio, A. R., & Crispino, J. D. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.11.004 · Cited by 38
Thromboinflammation in Myeloproliferative Neoplasms (MPN)—A Puzzle Still to Be Solved
Bhuria, V., Baldauf, C. K., Schraven, B. L., & Fischer, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063206 · Cited by 38
Stein, H., Bob, R., Dürkop, H., Erck, C., Kämpfe, D., Kvasnicka, H. M., Martens, H., Roth, A., & Streubel, A. (2015) · Leukemia · doi:10.1038/leu.2015.192 · Cited by 38
Metadata
- Authors
- Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., Aziz, A., Godfrey, A. L., Hinton, J., Martincorena, I., Van Loo, P., Jones, A. V., Guglielmelli, P., Tarpey, P., Harding, H. P., Fitzpatrick, J. D., Goudie, C. T., Ortmann, C. A., Loughran, S. J., Raine, K., Jones, D. R., Butler, A. P., Teague, J. W., O'Meara, S., McLaren, S., Bianchi, M., Silber, Y., Dimitropoulou, D., Bloxham, D., Mudie, L., Maddison, M., Robinson, B., Keohane, C., Maclean, C., Hill, K., Orchard, K., Tauro, S., Du, M.-Q., Greaves, M., Bowen, D., Huntly, B. J. P., Harrison, C. N., Cross, N. C. P., Ron, D., Vannucchi, A. M., Papaemmanuil, E., Campbell, P. J., & Green, A. R.
- ORCID
- Nangalia, J.
- Massie, C.E.
- Baxter, E.J.
- Nice, F.L.
- Gundem, G.
- Wedge, D.C.
- Avezov, E.
- Kollmann, K.
- Kent, D.G.
- Godfrey, A.L.
- Hinton, J.
- Martincorena, I.
- Jones, A.V.
- Guglielmelli, P.
- Tarpey, P.
- Harding, H.P.
- Fitzpatrick, J.D.
- Loughran, S.J.
- Raine, K.
- Jones, D.R.
- Teague, J.W.
- McLaren, S.
- Hill, K.
- Orchard, K.
- Du, M.-Q.
- Greaves, M.
- Bowen, D.
- Huntly, B.J.P.
- Harrison, C.N.
- Cross, N.C.P.
- Ron, D.
- Vannucchi, A.M.
- Papaemmanuil, E.
- Campbell, P.J.
- Green, A.R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-12-19
- Volume
- 369
- Issue
- 25
- Pages
- 2391-2405
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3966280
- OpenAlex
- W2138709799
- Cited by
- 1,756
- References
- 40
- Citations by year
- 2026: 64 · 2025: 59 · 2024: 72 · 2023: 90 · 2022: 112 · 2021: 133 · 2020: 125 · 2019: 124 · 2018: 130 · 2017: 181 · 2016: 208 · 2015: 239 · 2014: 208 · 2013: 7
- FWCI
- 108.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- University of Salford Institutional Repository (University of Salford) (submittedVersion, cc-by)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Leukemia and Lymphoma Society
- Leukemia and Lymphoma Research
- University of Salford Manchester
- Wellcome Trust (079249, 100140, 093867, 084812)
- University Hospital Southampton NHS Foundation Trust
- Cancer Research UK (12526, 12765, 15488)
- National Institute for Health and Care Research (NF-SI-0512-10079)
- Kay Kendall Leukaemia Fund
- University of Southampton
- KU Leuven
- Università degli Studi di Firenze
- Associazione Italiana per la Ricerca sul Cancro
- Vlaamse regering
- Canadian Institutes of Health Research
- Medical Research Council
- Cambridge Institute for Medical Research, University of Cambridge
- NIHR Cambridge Biomedical Research Centre
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- calreticulin, CALR mutation, myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, myelofibrosis, myelodysplastic syndrome, endoplasmic reticulum chaperone, clonal evolution, hematopoietic stem and progenitor cells, somatic mutations
- MeSH terms
- Amino Acid Sequence, Bone Marrow Diseases, Exons, Humans, Leukemia, Myeloid, Molecular Sequence Data, Mutation, Myelodysplastic Syndromes, Neoplasms, Thrombocythemia, Essential, Polymerase Chain Reaction, Sequence Analysis, DNA, Calreticulin, Janus Kinase 2, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
